Cybin Archives

Psychedelics News

Cybin

Industry

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

Breaking News

19 Feb 2026

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

By Madison Roberts

Industry

6 Dec 2023

Cybin Granted U.S. Patent For CYB003 Psilocybin Program

New patent provides IP protection until at least 2041. Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications....

By Microdose NewsDesk

Breaking News

30 Nov 2023

Cybin Reports Positive Topline Data from Phase 2 Study of Major Depressive Disorder

Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Uncategorized

25 Oct 2023

Cybin Granted Two New Patents For DMT Program

Cybin has added to this growing IP portfolio with the granting of two more patents for its DMT program....

By Microdose NewsDesk

Finance

13 Oct 2023

Cybin Shareholders Approve Acquisition of Small Pharma

Cybin shareholders approve the acquisition of Small Pharma with 99.4% of the vote....

By Microdose NewsDesk

Industry

22 Sep 2023

Cybin Completes Phase 2 Enrollment of CYB003 for Major Depressive Disorder

Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder....

By Microdose NewsDesk

Finance

18 Sep 2023

Billionaire Investor Steve Cohen Buys 19 million Shares of Cybin

Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin....

By Jason Najum

Industry

5 Sep 2023

Cybin Granted U.S. Patent for 5-MeO-DMT

The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs....

By Microdose NewsDesk

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result